LINFOMA DE CELULAS GRANDES ANAPLASICAS

Quiñonez-Chahín J, Graterol F, Súnico N,
Pérez-Alfonzo R, Oliver M.

Gobierno Bolivariano de Venezuela | Ministerio del Poder Popular para la Salud

- ♀ 41 años
- Natural y procedente de Caracas
- Antecedentes personales:
  - LES (Trombocitopenia) dx hace 3 años
  - Tto: Prednisona 40 mg/d (Med I. y Hematol.)
- Antecedentes familiares: NC



1 año de evolución



Planteamientos diagnósticos:

1. **Lupus Eritematoso Sistémico:**
   - **Trombocitopenia**
1. **Lupus Profundo (Paniculitis Lúpica) Vs.**
1. **Calcinosis Vs.**
1. **Lipomatosis**


4x


10x


40x

GB	13.500 /µL
Neutrófilos	60%
Linfocitos	40%
Hemoglobina	14,2 gr/dL
Hematocrito	45,6%
VCM	90,4 fL
CHCM	31,2 gr/dL
Plaquetas	79.000 /µL
PT	1,06
PTT	+6
Glucosa	96 mg/dL
Creatinina	0,9 mg/dL
AST	10 U/L
ALT	6 U/L
Bil. Total	0,9 mg/dL
VSG	20 mm/hora
HIV	Negativo
VDRL	No reactivo

INSTITUTO DE BIOMEDICINA

PARACLINICOS

CH-50: 88 UCH 50ml
AAN: Negativos

Acs. Anti-cardiolipinas : Negativos


cm
1
2
3
18-016-012-058-1201

Impresión diagnóstica:

- **Linfoma No Hodgkin de Células Grandes**

GB	11.200 /µL
Neutrófilos	71%
Linfocitos	22%
Hemoglobina	14,2 gr/dL
Hematocrito	45,6%
VCM	90,4 fL
CHCM	31,2 gr/dL
Plaquetas	66.000 /µL
LDH	270 U/L (VN: 100-190 U/L)
Beta 2 microglobulina	3,22 mg/L (VN: 0,85-2,20 mg/L)
Virus Linfotrópico (HTLV1)	No reactivo

PARACLINICOS

- **TAC de Tórax: DLN**
- **TAC Abdomino-pelvico: DLN**





Diagnostico Inmuno-histoquímico:

- **Linfoma de Células Grandes Anaplasicas (ALC, CD30 y CD45ro positivos)**







Diagnóstico definitivo:

- **LINFOMA DE CELULAS GRANDES ANAPLASICAS CD30+**

Tratamiento:

- **Quimioterapia multi-fármaco:**
  - **CHOP:**
    - **C**iclofosfamida
    - **H**idroxidaunorrubicina(Doxorrubicina)
    - **O**ncovin® (Vincristina)
    - **P**rednisona

Linfoma de Células Grandes Anaplasicas

REAL	EORTC	WHO
	Indolent	
MF/Sezary syndrome	MF	MF
	MF + follicular mucinosis	Variants: follicular mucinosis
	Pagetoid reticulosis	pagetoid reticulosis
Peripheral T-cell lymphoma	Large cell CTCL, CD30 positive	
	Anaplastic	Primary cutaneous anaplastic large cell lymphoma
	Pleomorphic	Peripheral T-cell lymphoma
	Immunoblastic	Peripheral T-cell lymphoma
	Lymphomatoid papulosis	Lymphomatoid papulosis (T-cell proliferation of uncertain malignant potential)
	Aggressive	
	Sézary syndrome	Sézary syndrome
	Large cell CTCL CD30 negative	Peripheral T-cell lymphoma
	Provisional	
	Granulomatous slack skin	MF variant
Provisional entity	CTCL-pleomorphic small/medium-sized	Peripheral T-cell lymphoma
Subcutaneous panniculitis-like T-cell lymphoma	Subcutaneous panniculitis-like T-cell lymphoma	Subcutaneous panniculitis-like T-cell lymphoma

REAL, Revised European American Classification; *EORTC*, European Organization for Research and Treatment of Cancer; *WHO*, World Health Organization; *MF*, mycosis fungoides; *CTCL*, cutaneous T-cell lymphoma.

LESIÓN CUTÁNEA CON RASGOS HP LTC CD30+

EXCLUIR

- **LTC CD30+ 2°MF** → **Tratar MF**
- **LACG CD30+** → **Protocolo Hemato-oncolog.**

ESTADIFICACIÓN

\+ → **Protocolo Hemato-oncolog.**

\-

ESPECTRO DE LOS TRASTORNOS LINFOPROLIERATIVOS CD 30+

- **Lesión localizada LCT CD30+** → **RADIOTERAPIA QX**
- **Múltiples que no desaparecen y aparecen** → **RADIOTERAPIA METOTREXATE**
- **Multifocales desconozco comportamiento** → **Esperar 4-8 semanas Aparecen-desaparecen**
  - NO → **RADIOTERAPIA METOTREXATE**
  - SI → **NO TRATAR METOTREXATE PUVA/UVB**
- **Lesiones múltiples Aparecen y desaparecen** → **NO TRATAR METOTREXATE PUVA/UVB**

Referencias Bibliográficas

- Rousell-Jones R: World health organization clssification of hematopoietic and linphoid tissues: Implications for dermatology. JAAD 2003; 48:93-102
- Willemze R et al: WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105:3768
- Kadin ME, Carpenter C: Systemic and primary cutaneous anaplastic large cell lymphomas. Semin Hematol 2003; 40:244
- Campo E et al: Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece. Histopathology 2006 Apr;48(5):481-504
- Bekkenk M, Geelen FAMJ, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30-positive lymphoproliferative disorders: long term follow-up data of 219 patients and guidelines for diagnosis and treatment. A report from de Dutch Cutaneous Lymphoma Group. Blood. 2000; 95:3653-61
- Ehrenfeld M, Abu-Shakra M, Buskila D Shoenfeld Y. The Dual Association between Lymphoma and Autoimmunity. Blood Cells, Molecules and Diseases 2001 Jul-Aug; 27(4): 750-756.